We are live on ! Find out more
ALXO icon

ALX Oncology

93 hedge funds and large institutions have $688M invested in ALX Oncology in 2023 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 33 increasing their positions, 16 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

330% more capital invested

Capital invested by funds: $160M → $688M (+$528M)

222% more call options, than puts

Call options by funds: $4.14M | Put options by funds: $1.29M

200% more funds holding in top 10

Funds holding in top 10: 13 (+2)

129% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 14

106% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 16

22% more funds holding

Funds holding: 7693 (+17)

11.81% more ownership

Funds ownership: 80.88%92.69% (+12%)

Holders
93
Holders Change
+17
Holders Change %
+22.37%
% of All Funds
1.36%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.04%
New
32
Increased
33
Reduced
16
Closed
14
Calls
$4.14M
Puts
$1.29M
Net Calls
+$2.85M
Net Calls Change
+$1.9M
Name Holding Trade Value Shares
Change
Change in
Stake
FA
101
Forefront Analytics
Pennsylvania
-$66.1K -13,769 Closed
Verition Fund Management
102
Verition Fund Management
Connecticut
-$55.9K -11,649 Closed
Two Sigma Advisers
103
Two Sigma Advisers
New York
-$55.7K -11,600 Closed
PCM
104
Prelude Capital Management
New York
-$52.3K -10,900 Closed
XT
105
XTX Topco
Cayman Islands
-$51.6K -10,740 Closed
Group One Trading
106
Group One Trading
Illinois
-$18.3K -1,932 Closed
NFSG
107
Newbridge Financial Services Group
Florida
-$106 -22 Closed

ALXO Hedge Fund Activity: Q4 2023 in Review

93 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q4 2023, worth a combined $688M — up 330% from $160M a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new ALXO positions and 14 closed out — a net gain of 18 holders — while 33 added to existing stakes and 16 trimmed.

The largest buyer was Cormorant Asset Management, adding an estimated $24M. The largest seller was Braidwell, exiting entirely with an estimated $6M sold.

  • 93 institutional investors held ALX Oncology (ALXO) as of Q4 2023, up from 76 in Q3 2023.
  • Funds reported $688M of ALX Oncology stock for Q4 2023, up 330% quarter-over-quarter.
  • 32 funds opened new ALX Oncology positions in Q4 2023 and 14 closed out, a net change of +18 holders.
  • The largest ALX Oncology buyer in Q4 2023 was Cormorant Asset Management, an estimated $24M added.
  • The largest ALX Oncology seller in Q4 2023 was Braidwell, an estimated $6M sold.

Based on aggregated 13F filings for Q4 2023.